Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for, or is in a course of clinical trials for, the treatment of Alzheimer's disease. This compound has also been successfully tested for the pretreatment of organophosphate poisoning. Organophosphate nerve agents are potent irreversible inhibitors of acetylcholinesterase in the central and also in the peripheral compartment. In this study Hup A in a higher dose (Soo micro S/kg) was tested as a prophylaxis against a high, mainly centrally acting, nerve agent (soman). According to the results obtained, Hup A in this dosage was not able to protect AChE against soman in both the peripheral and central compartments. The effect of Hup A and soman was found to be additive and all animal subjects died.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below